(Bloomberg) -- A plan by Hindustan Unilever Ltd.'s parent to buy GlaxoSmithKline Plc's Indian consumer business for 3.3 billion euros ($3.8 billion) in cash and shares is positive for the local unit's earnings, according to analysts, even as the price tag is said to be about $1 billion more than rival Nestle SA's offer.
Shares in Hindustan Unilever rose 4.1 percent on Monday to a record, while GlaxoSmithKline Consumer Healthcare Ltd. added 2.8 percent to its highest level since Sept. 21. In London, GlaxoSmithKline slumped 7.6 percent, the most in a decade, while Unilever NV was little changed in Amsterdam.
The buyout “is accretive from both an EPS and margin perspective” and “may lead to ~800-1000 basis points synergy on margins in a phased manner once the merger happens in 12 months time,” Jefferies analysts Varun Lohchab and Tanmay Sharma wrote in a report Monday.
For more on the $3.8 billion deal click here
Here's What Analysts Are Saying:
Credit Suisse (Arnab Mitra)
- Merger will make HUL's food and refreshment business 1.6x larger and give it a strong nutrition brand which can be leveraged in more categories
- Raises FY21 earnings estimates by 6.5 percent
- Maintains neutral, lifts PT to 1,900 rupees from 1,770 rupees
Citigroup (Jamshed Dadabhoy)
- Deal may take a year to complete given regulatory/shareholder approvals but it should be EPS accretive from day 1
- Even without synergy benefits, the merger is EPS accretive for HUL to the extent of ~3.7% on FY21 earnings estimates
- HUL may have to pay parent a royalty from Horlicks brand sales
Jefferies (Varun Lohchab)
- HUL's distribution footprint is ~3x GSK's, so it has potential to improve sales growth
- Valuations of Hindustan Unilever leave no room for error
- Maintains Hold, PT 1,650 rupees
Prabhudas Lilladher (Amnish Aggarwal)
- Synergy benefits will start accruing from FY21
- Expects one-time dividend in FY21, given that Glaxo has cash of 38 billion rupees ($539 million) on its books and Hindustan Unilever has 80 percent dividend payout
- Maintains hold, PT 1,880 rupees
To contact the reporter on this story: Abhishek Vishnoi in Singapore at avishnoi4@bloomberg.net
To contact the editors responsible for this story: Divya Balji at dbalji1@bloomberg.net, Margo Towie, Naoto Hosoda
©2018 Bloomberg L.P.
Watch the Hot Money debate on the HUL-GSK Consumer Health merger here:
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
